However, given recent reports of cardiac safety signals during the early clinical development of MCL1 inhibitors and the emerging biology of MCL1 in normal cardiomyocyte function45, the key question is whether inhibition of MCL1 is safe to pursue for the treatment of cancer. Here, MCL1 is linked to cancer.